Estimation and Validation of Gefitinib by using Rp- High Performance Liquid Chromatography. by Hitler, Ningthoujam
ʺ     ESTIMATION AND VALIDATION OF GEFITINIB BY USING
ʺRP- HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Dissertation submitted to
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY
 CHENNAI
In partial fulfillment for the award of degree of
MASTER OF PHARMACY
IN
DEPARTMENT OF PHARMACEUTICAL ANALYSIS
Submitted By
HITLER NINGTHOUJAM (Reg.No-26117431)
Under the guidance of
  Dr.  K.K.SENTHIL KUMAR  M. Pharm, Ph.D.,
HOD & ASSOCIATE PROFESSOR
DEPARTMENT OF PHARMACEUTICAL ANALYSIS
DEPARTMENT OF PHARMACEUTICAL ANALYSIS
CHERRAAN`S COLLEGE OF PHARMACY,
COIMBATORE-641039
APRIL- 2014
     CHERRAAN’S COLLEGE OF PHARMACY
              (Affiliated to the Tamilnadu Dr.M.G.R medical university, Chennai)
               Approved by The Govt. of Tamilnadu, Chennai
               All India Council for Technical Education, New Delhi
                Recognized by pharmacy council of India, New Delhi
CERTIFICATE
This  is  to  certify  that  the  Dissertation  entitled  “ESTIMATION AND VALIDATION OF
GEFITINIB BY USING RP- HIGH PERFORMANCE LIQUID CHROMATOGRAPHY”
Submitted to The Tamilnadu Dr. M.G.R Medical University, Chennai is a bonafide project work
of  Reg No: 26117431  carried out in the Department  of Pharmaceutical  Analysis,  Cherraan’s
college of pharmacy, Coimbatore for the partial fulfillment for the degree of Master of Pharmacy
under my guidance during the academic year 2013-2014.
This work is original and has not been submitted earlier for the award of any other degree or
diploma of this or any other university.
Place: Coimbatore
Date:                                                                         Dr. K.K. Senthil Kumar, M.Pharm, PhD.,
                       HOD and Associate Professor
                                                                                      Department of Pharmaceutical Analysis,
                                                                                              Cherraan’s college of Pharmacy          
                                                                                                  
                                                                                                  
521. Siruvani Main Road, Telungupalayam, Piruvu, Coimbatore 641039
Phone: 2311066, 2346194, 2343380 Fax: 0422-2341066 E-Mail:cihs2002@Yahoo.Co.In
     CHERRAAN’S COLLEGE OF PHARMACY
              (Affiliated to the Tamilnadu Dr.M.G.R medical university, Chennai)
               Approved by The Govt. of Tamilnadu, Chennai
               All India Council for Technical Education, New Delhi
                Recognized by pharmacy council of India, New Delhi
CERTIFICATE
          This is to certify that the Dissertation entitled “ESTIMATION AND VALIDATION OF
GEFITINIB BY USING RP- HIGH PERFORMANCE LIQUID CHROMATOGRAPHY”
submitted to The Tamilnadu Dr. M.G.R Medical University, Chennai, is a bonafide project work
Reg  No:  26117431 carried  out  in  the  Department  of  Pharmaceutical  Analysis,  Cherraan’s
college of pharmacy, Coimbatore for the partial fulfillment for the degree of Master of Pharmacy
under  the  guidance  of  Dr.  K.K  Senthil  Kumar,  M.Pharm,PhD., HOD,  Department  of
Pharmaceutical  Analysis,  Cherraan’s  College of Pharmacy,  Coimbatore,  during the academic
year 2013-2014.
  
Place: Coimbatore                                                          Dr. N. Thirumoorthy, M.Pharm, Ph.D.,
Date:                                                                                                Principal & HOD 
                                                                                                Department of pharmaceutics
                                                                                                Cherraan’s college of Pharmacy  
                                                                 
                                                                                                                        
521. Siruvani Main Road, Telungupalayam, Piruvu, Coimbatore 641039
Phone: 2311066, 2346194, 2343380 Fax: 0422-2341066 E-Mail:cihs2002@Yahoo.Co.In
                                                                                                    ABSTRACT
ABSTRACT
In the present work, RP-HPLC method has been developed for the quantitative estimation
of Gefitinib in Pharmaceutical formulations.
A rapid and sensitive RP-HPLC Method with UV detection (246 nm) for routine analysis
of Gefitinib in Pharmaceutical  formulation was developed using gradient  pump (LC-10AT vp
pump), The separations were achieved on a Agilents’s 5µ  C18 (2) 100A, 250X4.6mm, column
with UV detection at 246 nm. Chromatography was performed with mobile phase containing a
mixture of  0.1% Triflouroacetic  acid  and Methanol  (35:65 v/v)  with  flow rate  1  ml/min and
retention time at 3.8 min
.
 In the range of 5 -30µg/ml, the linearity of Gefitinib shows a correlation
co-efficient of 0.999. The proposed method was validated by determining sensitivity, accuracy,
precision, linearity, selectivity and system suitability parameters.
Key words: Gefitinib, RP- HPLC.
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Introduction
1. Analytical Chemistry Introduction:
                Analytical chemistry is the science of obtaining, processing, and communicating
information about the composition and structure of matter. In other words, it is the art and science
of determining what matter is and how much of it exists.
                     Defining analytical chemistry as the application of chemical knowledge ignores the
unique perspective that analytical chemists bring to the study of chemistry. The craft of analytical
chemistry is not in performing a routine analysis on a routine sample which more appropriately is
called chemical analysis, but in improving established analytical methods, in extending existing
analytical  methods  to  new  types  of  samples  and  in  developing  new  analytical  methods  for
measuring chemical phenomena.
                 Analytical chemists perform qualitative and quantitative analysis use the science of
sampling, defining, isolating, concentrating and preserving samples, set error limits, validate and
verify results through calibration and standardization perform separations based on differential
chemical properties create new ways to make measurements interpret data in proper content and
communicate results.
                     They use their knowledge of chemistry, instrumentation, computers and statistics to
solve problems in almost all areas of chemistry. For example, their measurements are used to
assure compliance with environmental and other regulations to assure the safety and quality of
food, pharmaceuticals and water to support the legal process to help physicians diagnose disease
and to provide chemical measurements essential to trade and commerce.
               Analytical chemists are employed in all aspects of chemical research in industry,
academia and government.  They do basic laboratory research develop processes and products
design instruments used in analytical analysis, teach and work in marketing and law. Analytical
chemistry  is  a  challenging  profession  that  makes  significant  contributions  to  many fields  of
science.
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1.1 PRINCIPLE OF CHROMATOGRAPHY
Chromatography  is  a  technique  by  which  a  mixture  sample  is  separated  into  components.
Although  originally  intended  to  separate  and  recover  (isolate,  purify  and  separation)  the
components of a sample today complete chromatography systems are often used to both separate
and quantify sample components.
The term “chromatography" was coined by the Russian botanist, Tswett, who demonstrated that,
when a plant extract was carried by petroleum ether through a column consisting of a glass tube
packed with calcium carbonate powder, a number of dyes were separated. He named this analysis
method  "Chromatographie"  after  "chroma"  and  "graphos",  which  are  Greek  words  meaning
"color" and “to draw" respectively.
1.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
High  performance  liquid  chromatography  is  basically  a  highly  improved  form  of  column
chromatography. Instead of a solvent being allowed to drip through a column under gravity, it is
forced through under high pressures of up to 400 atmospheres. That makes it much faster. It also
allows you to use a very much smaller particle size for the column packing material which gives a
much greater surface area for interactions between the stationary phase and the molecules flowing
past it. This allows a much better separation of the components of the mixture
The  other  major  improvement  over  column  chromatography  concerns  the  detection  methods
which can be used. These methods are highly automated and extremely sensitive.
A HPLC system is basically composed of
 Mobile phase
 Pump
 Injector
 Column
 Column oven
 Detector.
1. MOBILE PHASE(SOLVENT RESERVOIR)
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The most common type of solvent reservoir is a glass bottle. Most of the manufacturer’s
supply these bottles with special caps Teflon tubing and filters to connect to the pump inlet
t and to the spurge gas (Helium) used to Remove Dissolved air. Filtration is needed to
eliminate suspended Particles and organic impurities
        
.
                                     Fig:  HPLC Basic Instrument.
Solvent system:
The  mobile  phases  used  in  Reversed-Phase  Chromatography  are  based  on  a  polar  solvent,
typically water to which a less polar solvent such as acetonitrile or methanol is added. Solvent
selectivity is controlled by the nature of the added solvent in the same way as was described for
Normal-Phase Chromatography. Solvents with large dipole moments such as methylene chloride
and 1,2-dichloroethane interacts preferentially with solutes that have large dipole moments such
as nitro-compounds, nitriles, amines and sulfoxides. Solvents that are good proton donors such as
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chloroform,  m-cresol  and  water  interact  preferentially with  basic  solutes  such  as  amines  and
sulfoxides and solvents that are good proton acceptors such as alcohols, ethers, and amines tend to
interact best with hydroxylated molecules such as acids and phenols.
Solvent degassing system:
The constituents of the mobile phase should be degassed and filtered before use. Several methods
are  employed  to  remove  the  dissolved gases  in  the  mobile  phase.  They include  heating and
vacuum degassing with an aspirator, filtration through 0.45 filters, vacuum degassing with an air-
soluble membrane, helium purging ultra sonification or purging or combination of these methods.
HPLC systems are also provided an online degassing system which continuously removes the
dissolved gases from the mobile phase.
Gradient Elution:
Steady  changes  of  the  mobile  phase  composition  during  the  chromatographic  run  is  called
gradient  elution.  It  may be considered as  an analogy to the temperature programming in gas
chromatography.
The main purpose of gradient elution is to move strongly retained components of the mixture
faster, but having the least retained component well resolved.
Starting with the low content of the organic component in the eluent we allow the least retained
components to be separated. Strongly retained components will sit on the adsorbent surface on the
top of the column or will move very slowly.
When we start  to  increase  an amount  of  organic  component  in  the eluent  (acetonitrile)  then
strongly retained components will move faster and faster because of the steady increase of the
competition for the adsorption sites.
Gradient elution also increase quasi-efficiency of the column. In the isocratic elution, the longer a
component is retained the wider its peak. In gradient elution especially with the smooth gradient
shape without a flat regions the tail of the peak is always under the influence of the stronger
mobile phase when compared to the peak front. Thus molecules on the tail of the chromatographic
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zone (peak) will move faster.  This will tend to compress zone and narrow the resultant peak.
Performance of the gradient elution is strongly dependent on the instrumentation. 
Isocratic Elution :
In  this  technique,  the  same  mobile  phase  combination  is  used  throughout  the  process  of
separation. The same polarity or elute strength is maintained throughout the process. In isocratic
separation, mobile phase is prepared by using pure solvent or mixture of solvent i.e. , solvent of
same eluting power or polarity is used.
2.  PUMPS:
Pumps are used to   flow   mobile phase at high pressure and at controlled flow rates. The pumps
must be capable of generating pressure of up to 5000 psi at flow rates up to 3ml/min for analytical
purpose.  Pumps  used  in    preparative  scale  hplc  may be  required  to  pump at  flow rates  of
upto20ml/min. The pumping systems used in HPLC can be categorized in three different types.
            a. Reciprocating Pump 
                     -single Piston
                     -Dual Piston
            b.  Syringe pumps
            c.  Constant pressure pumps
• Pneumatic Pump
• Amplifier Pump
      d.   Displacement Pump
The first classification is according to the eluent flow rate that the pump is capable of delivering. 
a). RECIPROCATING PUMP: Reciprocating pumps are by far the most widely used and
practically 100% of the pumps used in commercial  HPLC equipment are of the reciprocating
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type. In reciprocating pumps, a motor driven reciprocating piston controls the flow of mobile
phase with the help of two ball check valves that opens and closes with then piston movement.
The flow is thus not continuous and damping of flow is necessary. This is accomplished using
pulse dampers which are a long coiled capillary tube.
 Single Piston Reciprocating Pump:
 The pump takes the form of a large metal syringe  the piston being propelled by an electric motor
and driven by a worm gear. The speed of the motor determines the pump delivery. Another motor
actuates the piston by a different system of gearing to refill the syringe rapidly when required. The
solvent is sucked into the cylinder through a hole in the center of the piston and between the
piston and the outlet there is a coil that acts as a dampener. This type of pump is still occasionally
used for the mobile phase supply to microbore columns that require small volumes of mobile
phase to develop the separation. It  is also sometimes used for reagent delivery in post column
derivatization as it can be made to deliver a very constant reagent supply at very low flow rates.
The single piston reciprocating pump was the first of its type to be used with high efficiency LC
columns (columns packed with small particles) and is still  very popular today. It  is simple in
design and relatively inexpensive.
Dual piston Reciprocating Pump:
A pump for producing a substantially smooth and continuous outflow of liquid at relatively high
pressure has two piston assemblies flow connected in series. The first piston assembly includes a
pressure piston having a long suction stroke and a relatively short and abrupt expulsion stroke. A
valve at the inlet of the pressurization piston allows flow to enter (but not exit) and a valve at the
outlet of the pressurization piston allows flow to exit (but not enter). The second piston assembly
includes a damper piston which functions as a mechanically driven damper to smooth the outflow
from the pressure piston. This smoothing is accomplished by storing of the liquid displaced by the
expulsion stroke of the pressure piston and then delivering the stored pressurized liquid to the
pump  outlet  during  the  suction  stroke  of  the  pressure  piston.  The  drive  for  the  pistons  is
constructed  to  produce  an  increased  outflow of  pressurized  liquid  for  a  short  interval  at  the
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beginning of the expulsion stroke of the pressure piston to compensate for compressibility of the
liquid at high pressure. At low pressure the stepper motor drive is slowed down in response to the
sensing of the increase of the outflow during this short interval to maintain the outflow smooth
and continuous during this part of the cycle of operation.
b) SYRINGE PUMPS:
 The first pumps to be used were syringe pumps which were in effect large stainless steel motor
driven hypodermic syringes. They provided a very constant flow rate which was virtually pulse
less but required a rather frequent, lengthy and involved refilling process. In addition unless some
form of marine engineering was employed the pumps could not operate at very high pressures.
Due to these disadvantages the syringe pump was soon replaced by piston pumps which, although
far from being pulse less, were much easier to operate. Today syringe pumps are rarely used in
mobile phase supplies but they are still used very effectively in both pre-column and post-column
reactors.  Their very constant  flow rate provides accurate reagent  addition and in post-column
reactors does not introduce detector noise.
C) CONSTANT PRESSURE PUMP:
Pneumatic Pump: The pneumatic pump is double piston pump one piston having a relatively
large diameter and the other a relatively small diameter. The two pistons are connected together
and fit inside two connected cylinders. The smaller cylinder is fitted with inlet and outlet non-
return valves. The large piston is driven by compressed air (the gas alternately driving the piston
in one direction and then the other) and actuates the smaller piston which pumps the liquid. The
system acts as a pressure amplifier as the output pressure from the pump with the smaller piston
will be equal to the pressure applied to the larger piston times the ratio of the cross-sectional area
of the larger piston to that of the smaller piston. This type of piston was originally used for normal
liquid chromatography separations but was found to be noisy and produced strong flow pulses
that  destabilized  the  detector.  It  is  now  used  almost  exclusively  for  slurry  packing  liquid
chromatography  columns.  It  is  the  simplest  type  of  pump  that  can  be  designed  to  provide
exceedingly high pressures common use they were the pneumatic pump where the necessary high
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pressures were achieved by pneumatic amplification and the syringe pump which was simply a
large strongly constructed syringe with a plunger that was driven by a motor. Today the majority
of  modern  chromatographs  are  fitted  with  reciprocating  pumps  fitted  with  either  pistons  or
diaphragms. For more information on HPLC pump requirements  see the pump section in  the
HPLC supplement. The pneumatic pump has a much larger flow capacity than the piston type
pumps  but  nowadays  is  largely  used  for  column  packing  and  not  for  general  analysis.  The
pneumatic pump can provide extremely high pressures and is relatively inexpensive, but the high
pressure  models  are  a  little  cumbersome  and  at  high  flow  rates  can  consume  considerable
quantities of compressed air.
The second classification is according to the construction materials and the final classification
Constant  pressure  pump  not  constant  flow can  deliver  high  pressures.The  Construction  of
materials to be used for Pumps should be inert towards the solvents to be used .
3. INJECTOR:
Sample introduction can be accomplished in various ways.  The simplest  method is to use an
injection valve. In more sophisticated LC systems, automatic sampling devices are incorporated
where the sample is introduced with the help of auto samplers and microprocessors. In liquid
chromatography,  liquid  samples  may  be  injected  directly  and  solid  samples  need  only  be
dissolved in an appropriate solvent. The solvent need not be the mobile phase but frequently it is
judiciously  chosen  to  avoid  detector  interference,  column/component  interference,  loss
inefficiency or all of these. It is always best to remove particles from the sample by filtering over
a 5 µm filter or centrifuging, since continuous injections of particulate material will eventually
cause blockages in injection devices or columns. Sample sizes may vary widely. The availability
of highly sensitive detectors frequently allows use of the small samples which yield the highest
column performance.
TYPES OF INJECTORS :
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a) Septum Injectors : For injecting the sample through a rubber septum. This is not common,
since the septum has to withstand high pressure.
b) Stop flow( on line ) Injectors : In which the flow of mobile phase is stopped for a while and
the sample is injected through a valve device.
c ) Rheodyne Injector ( Loop valve type) :  It  is the most popular injector. This has a fixed
volume loop like 20µl or 50µl or more. Injector has two modes, i.e.  ,  load position when the
sample is loaded in the loop and inject mode, the sample is injected .
Examples of injectors
                                                                             
Insertion of a sample onto the column must be as a narrow plug so that the peak broadening
attributable to this step is negligible. The injection system itself has no dead volume. 
4. COLUMN:
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The column is the heart of the chromatograph providing the means for separating a mixture into
components. The selectivity, capacity and efficiency of the column are all affected by the nature
of the packing material or the materials of construction. 
Requirements for an Ideal HPLC Column:
1. Particles should be spherical and available in particle diameters ranging from 3 to10 µm.
2. Particles should withstand typical pressures encountered during HPLC {(900-3000 psi (6.1-
20.5 MPa) but ideally up to 4000 psi (27.2 MPa)} and should not swell or shrink with the
nature of the eluent.
3. Particles should have porosity in the range 50-70 %, extending to 80 % for Size-Exclusion
Chromatography.
4. Particles should contain no pores smaller than ~60 A0 in diameter and should have a uniform
pore size distribution.
5. Particles should be available with a range of mean pore diameters of 60-1000 A0 .
6. The internal surface of the material should be homogeneous.
7. The  internal  surface  should  be  capable  of  modification  to  provide  a  range  of  surface
functionalities.
8. Packing  materials  should  be  chemically  inert  under  all  conditions  of  pH  and  eluent
composition.
9. The physico-chemical  characteristics of the material  should be reproducible from batch to
batch and from manufacturer to manufacturer.
10. The material should be readily available and relatively inexpensive and its chemical behavior
should be well understood.
There are  different columns are available
A. Guard Columns:  These columns are placed anterior to the separating column. This serve as a
protective  factor  that  prolongs  the  life  and  usefulness  of  the  separation  column. They  are
dependable columns designed to filter or remove
1) Particles that clog the separation column. 
2)Compounds  and  ions  that  could  ultimately  cause  "baseline  drift",  decreased  resolution,
decreased sensitivity, and create false peaks.
Department of Pharmaceutical Analysis Page 10
Introduction
3) Compounds that may cause precipitation upon contact with the stationary or mobile phase.
 B.  Derivatizing  Columns:  Pre-  or  post-primary column derivatization  can  be  an  important
aspect of the sample analysis. Reducing or altering the parent compound to a chemically related
daughter  molecule  or  fragment  elicits  potentially tangible  data  which may complement  other
results or prior analysis.
C. Capillary Columns: Advances in HPLC led to smaller analytical columns. Also known as
micro columns, capillary columns have a diameter much less than a millimeter and there are three
types:  open-tubular,  partially  packed,  and  tightly  packed.  They  allow the  user  to  work  with
nanoliter sample volumes, decreased flow rate, and decreased solvent volume usage which may
lead to cost effectiveness. 
D.  Fast Columns: One of the primary reasons for using these columns is to obtain improved
sample throughput (amount of compound per unit time). For many columns, increasing the flow
or migration rate through the stationary phase will adversely affect the resolution and separation.
Therefore, fast columns are designed to decrease time of the chromatographic analysis without
forsaking significant deviations in results.
E. Preparatory  Columns: These columns  are  utilized  when  the  objective is  to  prepare  bulk
(milligrams) of sample for laboratory preparatory applications. A preparatory column usually has
a large column diameter which is designed to facilitate large volume injections into the HPLC
system.
The heart of the system is the column. The choice of common packing material and mobile phases
depend on the physical  properties  of  the  drug.  The  column is constructed  from smooth bore
stainless steel tubing or heavy walled glass tubing to withstand high pressure.
F. Analytical Columns : Analytical columns is the most important part of the HPLC technique
which  decides  the  efficiency  of  separation.  There  are  several  stationary  phases  available
depending upon the technique or mode of separation used.
COLUMN PACKING:
The packing used in modern HPLC consist of small rigid particles having a narrow particle size
distribution. There are three main type of column packing in HPLC.
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 Porous, Polymeric Beads
 Porous Layer Beds
 Totally Porous Silica Particles (dia. <10 µm)
5. DETECTOR:
The detector converts a change in the column effluent into an electrical signal that is recorded by
the data system. There are different types of detectors used in HPLC. Liquid chromatographic
detectors  are  of  two  basic  types.  Bulk  property detectors  respond  to  a  mobile-phase  bulk
property,  such as refractive index, dielectric constant,  or density.  In  contrast,  solute property
detectors respond to some property of solutes, such as UV absorbance, fluorescence, or diffusion
current, that is not possessed by the mobile phase.
A)  Refractive  Index  Detector: The detection principle involves  measuring of the change in
refractive  index  of  the  column  effluent  passing  through  the  flow-cell.  The  greater  the  RI
difference between sample and mobile phase, the larger the imbalance will become. Thus, the
sensitivity will be higher for the higher difference in RI   between sample and mobile phase. On
the other hand, in complex mixtures, sample components may cover a wide range of refractive
index values and some may closely match that of the mobile phase, becoming invisible to the
detector.
B) UV Detector:  In these systems detection depends on absorption of UV ray energy by the
sample. They are capable to detect very wide range of compounds. The sensitivity ranges till
microgram quantity of estimation.
C) PDA detector: These are detectors which follow principle similar to UV detectors but the only
advantages are higher sensitivity and measure the entire absorption range i.e.  It  gives scan of
entire spectrum.
D) Evaporative Light Scattering Detector (ELSD):  In the ELSD, the mobile phase enters the
detector is evaporated in a heated device and the remaining solute is finally detected by the way it
scatters light. The intensity of the light scattered from solid suspended particles depends on their
particle size. Therefore, the response is dependent on the solute particle size produced. This, in
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turn, depends on the size of droplets generated by the nebulizer and the concentration of solute in
the  droplets.  The  droplet  size  produced  in  the  instrument  nebulizer  depends  on  the  physical
properties of the liquid and the relative velocity and flow-rates of the gas and liquid stream. The
importance  of  all  these  parameters  emphasizes  the  need  for  careful  design  and  rigorous
optimization of the instrument parts.
E)  Electro  Chemical  Detector: This  detector  is specially  suitable  to  estimate  oxidisable  &
reducible compounds .The principle is that when compound is either oxidized or reduced, the
chemical reaction produces electron flow. This flow is measured as current which is the function
of type and quantity of compound
F) Conductivity Detector: conductivity detector measures the conductivity of the mobile phase.
There  is  usually  background  conductivity  which  must  be  backed-off  by  suitable  electronic
adjustments. If the mobile phase contains buffers the detector gives a base signal that completely
overwhelms  that  from  any  solute  usually  making  detection  impossible.  Thus   the  electrical
conductivity detector is  a bulk property detector.  And senses all  ions whether  they are from a
solute or from the mobile phase.
G) Fluorescence detectors: Fluorescence detectors are probably the most sensitive among the
existing modern HPLC detectors.  It  is  possible  to detect  even a presence of  a  single analyte
molecule in the flow cell.  Typically, fluorescence sensitivity is 10 -1000 times higher than that of
the UV detector for strong UV absorbing materials. Fluorescence detectors are very specific and
selective  among  the  others  optical  detectors.  This  is  normally  used  as  an  advantage  in  the
measurement of specific fluorescent species in samples.
H) Mass Spectrometric Detection:  The use of mass spectrometer for hplc detection is becoming
common place, despite the high cost of such detector and need for a skilled operator. A mass
spectrometer can facilitate hlpc method development and avoid common problem by
 Tracking and identifying individual peaks in the chromatogram between experiments
 Distinguishing compounds of interest from minor compounds or interferences.
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 Recognizing unexpected and overlapping interference peaks to avoid a premature finish to
method development.
The function of  the detector  in  HPLC is to monitor  the mobile  phase as  it  merges  from the
column.
Detectors are of usually four types:
 Bulk Property Detectors
 Solute Property Detectors
 Desolvation detectors (flame ionization etc.)
 LC-MS detectors.
MOST COMMONLY USED METHODS IN HPLC:
The four main types of HPLC techniques are 
1. Normal-Phase Chromatography.
2. Reversed-Phase Chromatography.
3. Ion-Exchange Chromatography.
4. Size-Exclusion Chromatography.
Normal-Phase Chromatography :
The term "normal phase" is used to denote a chromatographic system in which a polar stationary
phase is employed and a less polar mobile phase is used for elution of the analytes. In the normal-
phase mode, neutral solutes in solution are separated on the basis of their polarity the more polar
the solute, the greater is its retention on the column. Since the mobile phase is less polar than the
stationary phase, increasing the polarity of the mobile phase results in decreased solute retention.
Normal-Phase chromatography is  most  commonly applied to the analysis of samples that  are
soluble in non-polar solvents and it is particularly well suited to the separation of isomers and to
class separations.
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Although the separation mode has occasionally been misidentified as reversed phase it is normal
phase by virtue of the fact that increased aqueous levels of the mobile phase reduce carbohydrate
retention and elution order follows carbohydrate polarity. 
Normal-phase  separations  have  occasionally  been  combined  off-line  with  Reversed-phase
chromatography  to  separate  a  wider  range  of  species  than  could  be  accomplished  by  either
technique alone. The feasibility of such a system however is contingent on the compatibility of
the normal-phase eluent with that of the reversed-phase column.
Reversed-Phase Chromatography:
Reversed-Phase Chromatography, the most widely used chromatographic mode is used to separate
neutral  molecules  in  solution  on  the  basis  of  their  hydrophobicity.  As  the  name  suggests,
Reversed-Phase Chromatography is the reverse of Normal-Phase Chromatography in the sense
that it involves the use of a non-polar stationary phase and a polar mobile phase. As a result, a
decrease in the polarity of the mobile phase results in a decrease in solute retention. Modern
Reversed-Phase  Chromatography  typically  refers  to  the  use  of  chemically  bonded  stationary
phases  where  a  functional  group  is  bonded  to  silica  for  this  reason  Reversed-Phase
Chromatography  is  often  referred  to  in  the  literature  as  Bonded-Phase  Chromatography.
Occasionally, however polymeric stationary phases such as polymathacrylate or polystyrene or
solid stationary phases such as porous graphitic carbon are used. Weak acids and weak bases for
which  ionization  can  be  suppressed,  may  be  separated  on  reversed-phase  columns  by  the
technique known as ion suppression. In this technique a buffer of appropriate pH is added to the
mobile phase to render the analyte neutral or only partially charged. Acidic buffers such as acetic
acid are used for the separation of weak acids and alkaline buffers are used for the separation of
weak bases.
The  analysis  of  strong  acids  or  strong  bases  using  reversed-phase  columns  is  typically
accomplished by the technique known as ion-pair chromatography (also commonly called paired-
ion or ion-interaction chromatography). In this technique, the pH of the eluent is adjusted in order
to encourage ionization of the sample for acids pH 7.5 is used and for bases pH 3.5 is common.
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Reversed-Phase Chromatography is the most popular mode for the separation of low molecular
weight (<3000) neutral species that are soluble in water or other polar solvents. It is widely used
in the pharmaceutical industry for separation of species such as steroids, vitamins and β-blockers.
Because  of  the  mobile  phase  in  Reversed-Phase  Chromatography  is  polar,  Reversed-Phase
Chromatography is suited to the separation of polar molecules that either are insoluble in organic
solvents or bind too strongly to the polar normal-phase materials.
Ion-Exchange Chromatography:
In  Ion-Exchange  Chromatography (IEC)  species  are  separated  on  the  basis  of  differences  in
electric charge. The primary mechanism of retention is the electrostatic attraction of ionic solutes
in solution to "fixed ions" of opposite charge on the stationary phase support.  The stationary
phase or ion exchanger is classified as an anion-exchange material when the fixed ion carries a
positive charge and as a cation exchanger when it carries a negative charge.
A specialized form of IEC is ion chromatography (IC) which is the name applied to the analysis
of inorganic anions, cations and low molecular weight, water-soluble organic acids and bases.
Although  any  HPLC  technique  used  to  separate  the  above  species  can  be  termed  ion
chromatography in  general  IC  involves  the  use  of  ion-exchange  columns  and  a  conductivity
detector. Ion chromatography itself can be sub classified. Suppressed IC involves the use of a
membrane  device  known as  a  suppressor  between  the  column and  the  detector  to  lower  the
response of the eluent and thereby enhance the signal from the solute; nonsuppressed or "single-
column" IC does not contain a suppressor.
Size-Exclusion Chromatography:
Size-Exclusion  Chromatography  (SEC)  is  a  convenient  and  highly  predictable  method  for
separating simple mixtures whose components are sufficiently different in molecular weight. For
small molecules, a size difference of more than about 10% is required for acceptable resolution;
for  macromolecules  a  twofold  difference  in  molecular  weight  is  necessary.  Size-Exclusion
Chromatography can be used to  indicate the complexity of  a  sample mixture and to provide
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approximate molecular weight values for the components. It is an easy technique to understand,
and  SEC can  be  applied  to  the  separation  of  delicate  bio  macromolecules  as  well  as  to  the
separation of synthetic organic polymers. 
Because SEC is a gentle technique, rarely resulting in loss of sample or reaction, it has become a
popular choice for the separation of biologically active molecules. Each solute is retained as a
relatively  narrow  band,  which  facilitates  solute  detection  with  detectors  of  only  moderate
sensitivity. One of the major applications of SEC is polymer characterization.
Applications of HPLC
1. Preparative HPLC refers to the process of isolation and purification of compounds. This
differs  from  analytical  HPLC,  where  the  focus  is  to  obtain  includes  identifications,
quantification, and resolution of a compound.
2. Chemical  separations can be accomplished using HPLC by utilizing the fact  that  certain
compounds have different migration rates given a particular column and mobile phase. Thus
the  chromatography can  separate  compounds  from each  other  using  HPLC the  extent  or
degree of separation is mostly determined by the choice of stationary phase and mobile phase.
3. Purification refers to the process of separating or extracting the target compound from other
(possibly structurally related)  compounds or  contaminants.  Each compound should have a
characteristic peak under certain chromatographic condition. The migration of the compounds
and  contaminants  through  the  column  need  to  differ  enough  so  that  the  pure  desired
compound can be collected or extracted without incurring any other undesired compound.
4. Identification  of  the  compounds  by  HPLC is  a  crucial  part  of  any  HPLC  assay.  The
parameters of this assay should be such that a clean peak of the known sample is observed
from the chromatograph. The identifying peak should have a reasonable retention time and
should be well separated from extraneous peaks at the detection levels, in which the assay
would be performed.
5. Quantification  of  compounds  by  HPLC is  the  process  of  determining  the  unknown
concentration  of  a  compound  in  a  solution.  It  involves  injecting  a  series  of  known
concentration of the standard compound solution onto the HPLC for detection. 
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6. The chromatograph of these known concentrations will give a series of peaks that correlate to
the concentration of the compound injected.
 ADVANTAGES: 
 HPLC  separations  can  be  accomplished  in  a  matter  of  minutes  in  some  cases  even  in
seconds.  High  resolution  of  complex  sample  mixture  into  individual  components  can  be
obtained.
• Rapid  growth  of  HPLC  is  also  because  of  its  ability  to  analyse  substances that  are
unsuitable for gas liquid chromatographic (GLC) analysis due to non-volatility or thermal-
instability.
• Quantitative analysis is easily and accurately performed and errors of less than 1 %   are
common to most HPLC methods.
• Depending on sample type and detector used it is frequently possible to measure 10-9 g or 1
ng of sample. With special detectors analysis down to 1012ng  has been reported.
DISADVANTAGES:
• HPLC  instrumentation  is  expensive  and  represents  a  major  investment  for  many
laboratories.
• It requires a proficient operator to handle the instrument.
• HPLC cannot handle gas samples.
• HPLC  is  poor  identifier.  It  provides  superior  resolution  but  it  does  not  provide  the
information that identifies each peak.
• Sample preparation is often required.
• Only one sample can be analyzed at a time.
• Finally there is at present time no universal and sensitive detector. 
 ANALYTICAL METHOD DEVELOPMENT
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Method development is done for
1) New products
2) Existing products
Methods  are  developed  for  new  products  when  no  official  methods  are  available.  Alternate
methods for existing (non-pharmacopoeial) products are developed to reduce the cost and time for
better precision and ruggedness. Trial runs are conducted, method is optimized and validated.
When  alternate  method  proposed  is  intended  to  replace  the  existing  procedure  comparative
laboratory data including merit/demerits are made available.
Selection of analytical method
First stage in the selection or development of method is to establish what is to be measured and
how accurately it should be measured. The following analytical techniques are usually employed
for estimations of different components in formulations:-
 Titrimetric and gravimetric
 Ultraviolet and visible spectrophotometry.
 Thin layer chromatography
 High performance liquid chromatography (HPLC)
 Gas Chromatography (GC)
 Atomic absorption spectrometry (AAS)
 Infra-Red absorption spectrophotometry.
Steps of method development
Documentation  starts  at  the  very  beginning  of  the  development  process  a  system  for  full
documentation of the development studies must be established. All data relating to these studies
must be recorded in laboratory notebook or an electronic database.
1. Analyte standard characterization
a)  All  known  information  about  the  analyte  and  its  structure  is  collected  i.e.,  physical  and
chemical properties, toxicity, purity, hygroscopic nature, solubility and stability.
b) The standard analyte (100% purity) is obtained. Necessary arrangement is made for the proper
storage (refrigerator, desiccators and freezer).
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c) When multiple components are to be analyzed in the sample matrix the number of components
is noted data is assembled and the availability of standards for each one is determined.
d)  Only those  methods  (MS,  GC,  HPLC etc.,)  that  are  compatible  with  sample  stability are
considered.
2. Method requirements
The goals or requirements of the analytical method that need to be developed are considered and
the analytical  figures  of merit  are  defined.  The required detection limits,  selectivity,  linearity,
range, accuracy and precision are defined.
3. Literature search and prior methodology
The  literature  for  all  types  of  information  related  to  the  analyte  is  surveyed.  For  synthesis,
physical and chemical properties solubility and relevant analytical methods. Books, periodicals,
chemical manufacturers and regulatory agency compendia such as USP / NF, AOAC and ASTM
publications are reviewed. Chemical Abstracts Service (CAS) automated computerized literature
searches are convenient.
4. Choosing a method
a) Using the information in the literatures and prints, methodology is adopted. The methods are
modified wherever necessary. Sometimes it is necessary to acquire additional instrumentation to
reproduce, modify, improve or validate existing methods for in house analytes and samples.
b) If there are no prior methods for the analyte in the literature from analogy the compounds that
are similar in structure and chemical properties are investigated and are worked out. There is
usually one compound for which analytical method already exist that is similar to the analyte of
interest.
5. Instrumental setup and initial studies
a) The required instrumentation is setup. Installation, operational and performance qualification of
instrumentation using laboratory standard operating procedures (SOP’s) are verified.
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b)  Always  new  consumables  (e.g.  solvents,  filters  and  gases)  are  used  for  example  method
development is never started on a HPLC column that has been used earlier.
c) The analyte standard in a suitable injection / introduction solution and in known concentrations
and solvents are prepared. It is important to start with an authentic known standard rather than
with a complex sample matrix. If the sample is extremely close to the standard (e.g., bulk drug)
then it is possible to start work with the actual sample.
d) Analysis is done using analytical conditions described in the existing literature.
6. Optimization
During optimization one parameter is changed at a time, and set of conditions are isolated, rather
than using a trial and error approach. Work has been done from an organized methodical plan, and
every step is documented (in a lab notebook) in case of dead ends.
7. Documentation of analytical figures of merit
The  originally  determined  analytical  figures  of  merit  limit  of  quantitation  (LOQ),  limit  of
detection (LOD), linearity, time per analysis, cost, sample preparation etc., are documented.
8. Evaluation of method development with actual samples
The sample solution should lead to unequivocal, absolute identification of the analyte peak of
interest apart from all other matrix components.
9. Determination of percent recovery of actual sample and demonstration of
Quantitative  sample analysis:
Percent  recovery of  spiked,  authentic  standard analyte into a  sample matrix  that  is  shown to
contain no analyte is determined. Reproducibility of recovery (average +/- standard deviation)
from sample  to  sample and  whether  recovery has  been  optimized  has  been  shown.  It  is  not
necessary to obtain 100% recovery as long as the results are reproducible and known with a high
degree of certainty. The validity of analytical method can be verified only by laboratory studies.
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Guidelines  for analytical  Method validation.
For pharmaceutical method guidelines are prescribed by
 United State Pharmacopoeia (USP)
 Food and Drug Administration (FDA)
 World Health Organization (WHO)
 International Conference on Harmonization (ICH)
These Guidelines provide a framework for performing validation. In general, methods for routine
analysis, standardization or regulatory submission must include studies on specificity, linearity,
accuracy, precision, range detection limit, quantitation limit and robustness.
United  State Pharmacopoeia (USP):
USP  defines  analytical  method  validation  as  “The  process  by  which  it  is  established;  by
laboratory studies that performance characteristics of method meet the requirement for intended
analytical application”.
Food and Drug Administration (FDA):  FDA defines validation as “Establishing documented
evidence,  which provides  a high degree of  assurance that  a specific process will  consistently
produce meeting its pre- determined specification and quality attributes”.
World Health Organization (WHO):
WHO  defines  validation  as  “Process  of  providing  documented  evidences  that  a  system  /
procedure dose what it is supposed to do precisely and reliably”.
International Conference on Harmonization (ICH):
ICH is  tripartite  agreement  between European community,  USA and Japan.  Its  purpose is  to
provide a forum for constructive dialogue between regulatory authorities and Pharmacy industry
on real and perceived differences in technical requirements for product registration in European
community, USA and Japan.
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Objective is lying down of minimum standards applicable uniformly, irrespective of where the
product is manufactured or marketed in the three regions.
The  ICH  documents  give  guidance  on  the  necessity  for  revalidation  in  the  following
circumstances.
 Changes in the synthesis of the drug substances and
 Changes in the composition of the drug product 
Validation:
It  presents  a  discussion  of  the  characteristics  for  consideration  during  the  validation  of  the
analytical procedures included as part of registration applications submitted within the EC, Japan
and USA. This document does not necessarily seek to cover the testing that may be required for
registration in or export to other areas of the world. Furthermore this text presentation serves as a
collection of  terms  and  their  definitions  and  is  not  intended  to  provide  direction  on how to
accomplish validation. These terms and definitions are meant to bridge the differences that often
exist between various compendia and regulators of the EC, Japan and USA.
The objective of validation of an analytical procedure is to demonstrate that it is suitable for its
intended purpose. A tabular summation of the characteristics applicable to identification, control
of impurities and assay procedures is included. Other analytical procedures may be considered in
future additions to this document
.
Method validation is the process used to confirm that the analytical procedure employed for a
specific test is suitable for its intended use. Results from method validation can be used to judge
the quality,  reliability and consistency of analytical  results;  it  is  an integral  part  of any good
analytical practice.
T   ypes of Validation  :
Prospective validation: This is performed for all new equipments, products and
processes. It is a proactive approach of documenting the design
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specifications and performance before the system is operational. This is the
most defendable type of validation.
Concurrent Validation: This is performed in two instances i.e., for existing  Equipment
verification of proper installation along with specific Operational tests is done. In case
of an existing, infrequently made Product data is gathered from at least three successful
trials.
Retrospective validation: 
This is establishing documented evidence that the  Process is performed satisfactory and
consistently over time, based on review  and analysis of historical data. The source of
such data is production and QA/QC records. The issues to be addressed here are changes
to equipment, process, specifications and other relevant changes in the past
Analytical methods need to be validated or revalidated before their introduction into routine use
whenever the conditions change for which the method has been validated (e.g., an instrument with
different characteristics or samples with a different matrix) and whenever the method is changed
and the change is outside the original scope of the method.
The  validity  of  a  specific  method  should  be  demonstrated  in  laboratory  experiments  using
samples or standards that are similar to unknown samples analyzed routinely. The preparation and
execution should follow a validation protocol, preferably written in a step by- step instruction
format. This proposed procedure assumes that the instrument has been selected and the method
has  been  developed.  It  meets  criteria  such  as  ease  of  use  ability to  be automated  and  to  be
controlled  by computer  systems,  costs  per  analysis,  sample  throughput,  turnaround time  and
environmental, health and safety requirements.
The validation characteristics
1. Specificity
2. Accuracy
3. Linearity
4. Precision
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5. Limit of detection(LOD) & Limit of Quantification(LOQ) 
6. Range
7. Robustness
8. Systen suitability Parameters
1. SPECIFICITY
a)  Identification:  Discrimination  between compounds of  closely related  structures  which  are
likely to be present.
b)  Assay  and Impurity  test:  For  chromatographic  procedures,  representative  chromatogram.
Resolution of the two compounds which elute closest together. In case of non- specific assay is
used, a combination can be applied. Titration for assay, suitable test for impurities.
c) Impurities are available:  Assay:  Spiking pure substance (drug substance or drug product)
with  appropriate  levels  of  impurities  and/or  excipients.  Assay result  unaffected.  Impurity test
spiking drug substance or drug product with appropriate levels of impurities and demonstrating
separation.
d)  Impurities  not  available:  Samples  stored  under  relevant  stress  conditions  assay:  the two
results are compared impurity test: impurity profiles are compared, Peak purity test, diode array,
mass spectrometry.
2. ACCURACY
General 15 determinations over 3 concentrations covering specified range, upper and
lower concentrations 6 replicates middle one 3 replicates.
Reporting;
 % Recovery or
 Difference between mean and accepted true value
 Confidence interval
 Drug substance
 Application of analytical procedure to analyte of known purity( reference material).
 Drug product
 Placebo + drug substance
 adding known quantities of drug substance to drug product
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 Impurities(Quantification)
 Adding known quantities of impurities to drug product
 Placebo + impurities
 The individual or total impurities are determined e.g. weight/weight or area percent, in all
cases with respect to the major analyte
3. LINEARITY
Linearity should be established across the range.
Minimum 5 concentrations:
 dilution standard stock solution
 separate weighing of synthetic mixtures
Linear relationship, regression analysis
 Correlation coefficient
 y-intercept
 Slope of regression line
 Residual sum of squares.
4. PRECISION
 Repeatability:
 6 determinations at 100% of test concentration
 Intermediate precision
 Different days
 Analysts
 Equipment
 Not necessary to study these effects individually (2 x 6 determinations at 100 % of test
concentration).
 Recommended data
 Standard deviation
 Relative standard deviation
 Confidence
5 .LIMIT OF DETECTION(LOD) & LIMIT OF QUANTIFICATION(LOQ)
 Limit of detection of an individual analytical method is the lowest concentration/amount
of analyte in a sample that the method can detect but not necessarily quantify under the
Department of Pharmaceutical Analysis Page 26
Introduction
stated  experimental  conditions.  The  LOD will  not  only  depend  on  the  procedure  of
analysis but also on the type of instrument.
(DL) =3.3×σ\ S mcg/ml
 Where, σ = standard deviation of the response.
S = slope of the calibration curve.
 The slope S may be estimated from the calibration curve of the analyte.
 The estimate of σ may be carried out in a variety of ways.
 Limit of quantification of an individual analytical method is the lowest concentration/
amount of  analyte in  a  sample,  which can be quantitatively determined with suitable
precision and accuracy under stated experimental conditions. The quantification limit is
used particularly for the determination of impurities and/ or degradation products. The
LOQ  will  not  only  depend  on  the  procedure  of  analysis  but  also  on  the  type  of
instrument.
 (QL) =10×σ\ S mcg/ml
Where, σ = standard deviation of the response
S = slope of the calibration curve
6. RANGE
Assay of drug substance or finished product; 80 - 120 % of test solution.
 Impurity (quantification); reporting threshold to 120% of acceptance criteria.
 Assay and impurity; One test with 100 % standard
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 Linearity; Reporting threshold to 120 % assay acceptance criterion.
 Content uniformity; 70 - 130 % of test concentration
 Dissolution testing; ± 20% over specified range
 Drug release testing; 20% after 1 hour up to 90% after 24 hours 0-110 % of label claim
7. ROBUSTNESS:
 Variations: ·
 Stability of analytical solutions ·
 Different equipment ·
 Different analysts
 HPLC:
 Influence of pH in mobile phase
 Variations in mobile phase
 Different column
 Temperature
 Rate Flow
8. SYSTEM SUITABILITY PARAMETERS
System suitability tests are most often applied to analytical instrumentation. They are designed to
evaluate the components of the analytical system in order to show that the performance of the
system meets the standard required by the method. After the method has been validated an overall
system suitability tests should be routinely run to determine if the operating system is performing
properly.
System suitability tests are integral part of the gas and liquid chromatographic methods. They are
used to verify that the resolution and reproducibility of the chromatographic system are adequate
for analysis
.The following information furnishes the parameters used to calculate the system performance
values for the separation of two chromatographic components.
 Relative rétention (selectivity):
α = (t2-ta) / (t1-ta)
Where,
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α = Relative retention.
t1 = Retention time of the first peak measured from point of injection.
t2 = Retention time of the second peak measured from point of injection.
ta = Retention time of an inert peak not retained by the column, measured from point of injection.
 Theoretical plates:
n = 16 (t / w) 2
Where, n = Theoretical plates.
t = Retention time of the component.
w = Width of the base of the component peak using tangent method.
 Capacity factor:
K1 = (t2 / ta) – 1
Where K1 = Capacity factor.
 Resolution:
R = 2 ( t2 - t1 ) / ( w2 + w1 )
Where, R = Resolution between a peak of interest (peak 2) and the peak preceding it (Peak 1).
W2 = Width of the base of component peak 2.
W1 = Width of the base of component peak 1.
 Peak asymmetry:
T = W0.05 / 2f
Where,   T = Peak asymmetry or tailing factor.
W0.05 = Distance from the leading edge to the tailing edge of the peak, measured at a point 5 %
of the peak height from the baseline.
f = Distance from the peak maximum to the leading edge of the peak.
 Plates per meter:
N = n/ L
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Where, N = Plates per meter.
L = Column length in meters.
HETP = L / n
 Linear fit:
A linear calibration fit determines the best line (linear regression) for a series of calibration points.
A minimum of two calibration points is required to determine a linear fit.
The equation for calibrating the uncorrected amount is:
[Y = a X + b]
Where, Y = Component area or height.
a = Slop of the calibration line.
X = Uncorrected amount.
b = Y- axis intercept of the calibration line.
STATISTICAL ANALYSIS:
Statistical procedures and representative calculations:
The consistency and suitability of the developed method are substantiated through the statistical
analysis like standard deviation, relative standard deviation and theoretical plates per meter.
For Accuracy:
Standar deviation =σ=
Where, x = sample, xi = mean value of samples, n = number of samples
Relative Standard Deviation = σ/xi × 100
Molar extinction coefficient (mol-1 cm-1) = A/C × L
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Where, A= Absorbance of drug
C= concentration of drug
L= Path length
Sandell’s sensitivity (µg/ cm2/0.001 absorbance units) = C/A×0.001
Where, C= concentration of drug
A= Absorbance of drug
Unit- (mcg/cm2) =0.001 absorbance)
Coefficient of variance (σ) = Σ(x-x) 2/ n-1
Regression Equation y = a+ b x
Slope = y/x
Where, x = Concentration, y= Absorbance, a= Intercept
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                                                  LITERATURE REVIEW
Gefitinib is an orally administered synthetic anticancer drug and few analytical methods found in
literature for the quantitative estimation in bulk drug and pharmaceutical formulations.
 K.  Ravi  Shankar,  et  al.32,  has  reported  the  development  and  validation  of  sensitive
reverse  phase  HPLC  method  for  the  determination  of  gefitinib  in  bulk  and  in  its
pharmaceutical formulation. A rapid and sensitive RP-HPLC method with UV detection
at 205 nm for routine analysis of Gefitinib in bulk and pharmaceutical formulations was
developed. Chromatography was performed with mobile phase containing a mixture of
acetonitrile and 0.5% M ammonium dihydrogen phosphate buffer in the ratio of 30 : 70
v/v with flow rate 1.0 ml/min. The calibration curve of Gefitinib was found to be linear
over the range of 0.05 to 0.15 mg/ml with correlation coefficient  of 0.99.  Sensitivity,
accuracy, range, precision, robustness, ruggedness, stability, specificity, LOD, LOQ and
system suitability parameters were validated for the developed method.
 Subhash Chandra Bose,  et al  33,  have reported the quanlitative analysis of gefitinib by
quadrupole – time of flight (LCMS) coupled with PDA and ELSD detector, using dual
electro spray ionization (dual ESI ) multistage tandem mass spectrometry (LC-MS) were
used to identify of Gefitinib in tablet dosage form for validated and estimation. Efficient
chromatographic separation of analyte was achieved on Agilent XDB-C18 column ( 4.6 ×
50  mm,  1.8  µm)  using  an  isocratic  elution  mode  with  a  mobile  phase  comprised
acetonitrile and 0.1 % formic acid in water (75:25, v/v). The flow rate was 500µl / min .
The developed LC-MS method is validated with a respect to linearity, accuracy, precision,
specificity,  limit  of  detection,  limit  of  quantification  and robustness.  The method was
observed to be limit of detection and limit of quantification was found to be 5.56 ppm and
11.12 ppm respectively.  The method was successfully used for applied the quantitative
determination of Gefitinib in tablet formulation.
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 P.V.V .Satyanarayana,  et al  34.,  has reported the development and validation of liquid
chromatography method for the estimation of gefitinib in pharmaceutical dosage form.
A  simple,  specific,  accurate  and  precise  reverse  phase  high  performance  liquid
chromatographic method was developed and validated for the estimation of Gefitinib in
tablet dosage form. An Inertsil  ODS C-18, 5µm column having 250 x 4.6mm internal
diameter  in  isocratic  mode  with  mobile  phase  containing  acetonitrile:  methanol:
tetrahydrofuran in the ratio of 20:70:10 (v/v/v) was used. The flow rate was 1.0ml/min and
effluents were monitored at 251nm. The retention time for Gefitinib was 4.282min. The
method was validated for linearity, accuracy, precision, specificity, limit of detection, limit
of quantification and robustness. Limit of detection and limit of quantification were found
to be 0.09ppm and 0.29ppm respectively and recovery of Gefitinib from tablet formulation
was  found  to  be  99.16%.  The  proposed  method  was  successfully  applied  for  the
quantitative determination of Gefitinib in tablet formulation
 Lionel Faivre, et al.35,has  a simple HPLC-UV method for the simultaneous quantification
of gefitinib   and erlotinib in human plasma. Gefitinib and erlotinib are two tyrosine kinase
inhibitors  (TKI)  approved  for  the  treatment  of  advanced  non-small  cell  lung  cancer
(NSCLC).  Published  methods  for  simultaneous  analysis  of  erlotinib  and  Gefitinib  in
plasma are exclusively based on mass spectrometry.  The purpose of this study was to
develop a simple and sensitive HPLC-UV method to simultaneously quantify these two
TKI in  plasma. Samples were eluted at a flow rate of 0.4 ml / min throughout the 15-min
run. Dual UV wavelength mode was used, with gefitinib and erlotinib at 331 nm . The
calibration was linear in the range 20-1000 ng / ml and 80-4000 ng / ml for gefitinib and
erlotinib respectively.  This simple, sensitive, accurate and cost-effective method can be
used in routine clinical practice to monitor Gefitinib or erlotinib concentrations in plasma
from NSCLC patients.
 V. kalyana Chakravarthy, et al.36, have reported the development and validation of RP –
HPLC  method for the estimation of gefitinib in bulk and its pharmaceutical formulation.
Separation was achieved with a Kromasil 100-5, C18 (150 mmx4.6 mm I.D; particle size
5  µm)  and  Potassium  dihydrogen  phosphate  Buffer  pH  2.4:  Acetonitrile:  Methanol
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(65:21:14) as eluent at flow rate 1.5 ml/min. UV detection was performed at 250 nm . The
method is simple, rapid and selective. The described method of gefitinib is linear over a
range of 75.02 to 225.06 µg/ml . The method precision for the determination of assay was
below 2.0 %RSD. The percentage recoveries of active pharmaceutical  ingredient (API)
from dosage forms ranged from 100.5 to 101.1. The method is useful in the quality control
of Bulk and pharmaceutical formulations.
 Stephane Bouchet, et al 37, has reported the simultaneous determination of nine tyrosine
kinase inhibitors by 96- well solid phase extraction and ultra performance  LC/MS-MS.
 Ling- Zhi Wing, et al.38, has reported a novel, rapid and specific liquid chromatography-
tandem mass spectrometric (LC-MS / MS) method was developed and validated for the
simultaneous  quantification  of  Gefitinib  and  its  predominant  metabolite,  o-desmethyl
gefitinib in human plasma. Chromatographic separation of analyte was achieved on an
Alltima C18 anlytical HPLC column (150 mm × 2.1 mm,  5µm ) using an isocratic elution
mode with a mobile phase comprised acetonitrile and 0.1 % formic acid in water (30:70
v/v). The flow rate was 300  µl / min.) . The chromatographic run time was 3 min. The
column effluents were detected by API 4000 triple quadrupole mass spectrometer using
electro spay ionization (ESI). Linearity was in the range of 5-1000 ng / ml for Gefitinib
and 5-500 ng / ml for o-desmethyl Gefitinib and accuracies range from 89.7 to 104.7 %
for Gefitinib and 100.4 to 106.0 % for o-desmethyl Gefitinib. The results of this study
enabled clinicians to acertain the safety of the combination therapy of hydroxychloroquine
and Gefitinib in patients with advanced non-small cell lung cancer (NSCLC).
 P.  Pravalika  Reddy,  et  al.39, has  reported  new  spectrophotometric  methods  for  the
estimation of gefitinib in bulk drug and formulations. Two simple, precise and accurate
spectrophotometric methods were developed for the estimation of Gefitinib in bulk drug
and in pharmaceutical formulations. Method A and B is based on oxidation of followed by
coupling  of  3-  metyl-1,2-benzothiazolinone  hydrazone  (MBTH)  with  Gefitinib  using
Ferric chloride and Cerric ammonium nitrate(CAN) and measuring the chromogen at the
λmax  of  438  and  675  respectively.  Both  the  methods  follow  beer’s  law  in  the
concentration range of 100-700 µg/ml with MBTH and FeCl3 and 50-250 µg/ml with
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MBTH and CAN. The accuracy of the methods was determined by recovery studies. The
methods showed good reproducibility and recovery with relative standard deviation (in %)
less than 2. The methods were found to be simple, economical, accurate and reproducible
and can  be used for  routine analysis  of  Gefitinib  in  bulk drug and  in  pharmaceutical
formulations.
 R. Honey Well,  et al.40,  has reported simple and selective method for determination of
various tyrokinase inhibitors used in the clinical setting by liquid chromatography tandem
mass spectrometry.
 Sandra Roche, et al.41, has reported the development and application of novel analytical
methods for molecularly targeted cancer therapeutics. Based on LC-MS/MS techniques,
novel sensitive analytical  methods were developed for the quantification of 1) tyrosine
kinase inhibitor anti-cancer drugs  to examine the interaction of these agents with drug
resistance mechanisms and 2) the multiple myeloma drug thalidomide as a pilot study to
identify potential correlations between serum drug levels and toxicity/efficacy. Acquired
resistance to chemotherapeutics  through the over-expression of ABC transport  proteins
has presented a significant clinical challenge.  The up-regulation of ABC transporters such
as  P-glycoprotein  (P-gp),  Breast  Cancer  Resistant  Protein  (BCRP)  and  Multidrug
Resistance Protein (MRP-1) is an important cellular mechanism of resistance in vivo and
in vitro.  Using cell-line models and the developed LC-MS/MS quantification method it
was  established  that  dasatinib  an  agent  used  in  treatment  of  chronic  myelogenous
leukemia is a substrate of ABC transporters P-gp and BCRP but not of MRP-1, and that
dasatinib does not inhibit these transporters at clinically relevant concentrations.  Another
Tyrosine Kinase Inhibitor (TKI) being used in breast cancer, Lapatinib was shown to be
an inhibitor of P-gp but not a substrate of this resistance mechanism. Levels of other TKIs
were also found to vary in their uptake in primary models of brain cancer.  Using LC-
MS/MS, the circulating serum levels of thalidomide in multiple myeloma patients were
studied.  A clear correlation between dosing regime and serum level was seen however the
research  also unearthed  evidence  of  a  significant  incidence  of  non- compliance  which
could have far reaching consequences for patient treatment.  Overall, LC-MS/MS methods
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for the quantification of chemotherapeutic agents in complex biological matrices produced
sensitive and accurate data which we successfully exploited to characterize resistance to
new drugs and examine correlations between serum levels and treatment variables.
 Yoichi Nakamura, et al.42, has reported pharmacokinetics of Gefitinib predicts anti tumor
activity for advanced non- small cell lung cancer. Plasma trough levels of Gefitinib were
measured on days 3 (D3) and 8 (D8) by high performance liquid chromatography in 44
patients with advanced NSCLC treated with 250 mg Gefitinib daily. The median plasma
Gefitinib values were 662 ng / ml on D3 and 1064 ng / ml on D8 and the D8/D3 ratio was
1.587. The median progression-free survival (PFS) was 71 days and the median overall
survival  was 224 days.  Adenocarcinoma never  smoking and high D8 /  D3 ratio  were
associated with better PFS. Overall survival was not associated with D8 / D3 ratio. A high
D8 /  D3 ratio  was independently  associated  with  better  PFS in  patients  with  NSCLC
treated with gefitinib. Our finding suggest that the pharmacokinetics of Gefitinib may be
involed in its anti-tumor activity.
 N.  Appalaraju,  et  al  43., A  simple,  precise,  rapid  and  accurate  RP-  HPLC  method
developed for the estimation of Gefitinib in tablet dosage form. An Hypersil BDS RP C18,
250x4.6 mm, 5 m particle  size,  with  mobile  phase consisting of  0.02 M Dipotassium
Hydrogen orthophosphate and Methanol in the ratio of 10:90 v/v was used. The flow rate
was 1.0 ml/min and the effluents were monitored at 246 nm. The retention time was 3.7
min. The detector response was linear in the concentration of 25-300g/ml. The respective
linear regression equation being Y= 94342.26x+77672.7. The limit of detection and limit
of  quantification  was  0.125g/ml  and  0.15g/ml  respectively.  The  percentage  assay  of
Gefitinib was 99.5 %. The method was validated by determining its accuracy, precision
and  system  suitability.  The  results  of  the  study  showed  that  the  proposed  RP-HPLC
method is simple, rapid, precise and accurate, which is useful for the routine determination
of Gefitinib in bulk drug and in its pharmaceutical dosage form
 N.A.G .Lankheet, et al.44, has developed a fast and accurate method for determination of
anticancer  tyrosine kinase inhibitors (TKIs)  Gefitinib in human plasma was developed
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using  high  performance  liquid  chromatography  and  detection  with  tandem  mass
spectrometry  (HPLC-MS/MS).  Plasma  proteins  were  precipitated  and  a  aliquot  of
supernatant was directly injected onto a reversed phase chromatography system consisting
of a Gemini C18  column (50×2.0 mm,  5.0µm particle size) and then compounds were
eluted with a gradient.This method was validated over a linear range from 20.0 to 10,000
ng / ml for Gefitinib. Results from the validation study demonstrated good intra and inter
assay  accuracy  (<13.1  %)  and  precision  (10.0  %)  for  all  analyte.  This  method  was
successfully applied for routine therapeutic drug monitoring purposes in patients treated
with the investigated TKIs.
 Sano Kazumi, et al.45, has reported the quantitation of major metabolite of Gefitinib using
HPLC and LC –MS. Our objective is measuring the plasma concentrations of Gefitinib
and its  major metabolite.  The metabolites  were  generated in vitro  by enzyme reaction
using CYP2D6 or 3A4 produced using baculovirus. Reaction mixtures were analyzed by
HPLC and LC-MS. Major metabolites, O-desmethyl-gefitinib (M1) and minor metabolites
(M2, M3) were determined based on molecular weight using LC-MS. In this study we
have got effective findings to analyze Gefitinib metabolism.
 Ratna Kumari,et al 46. has reported a  UV Spectrophotometric method was developed for
the quantitative estimation of Gefitinib in bulk drug and tablet dosage forms. Gefitinib is a
drug that is used to treat several types of lung cancer and in particular, it is used alone for
the treatment of patients with a specific type of lung cancer termed non - small cell lung
cancer (NSCLC) that has not responded to chemotherapy.  It  works by preventing lung
cancer  cells  from growing & multiplying.   The drug exhibits  absorption maximum at
252nm in 0.1N HCL and obeys Beer’s law in the concentration range of 10-35µg/ml. The
method was extended to pharmaceutical preparations and there is no interference from any
common pharmaceutical additives
 Ming Zhao,  et  al.47, has  reported a  specific  method for  the determination of gefitinib
using HPLC coupled to tandem mass spectrometry.
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 Goukanapalli Chandra Sekara Reddy, et al.48, have reported the convergent approach
for commercial synthesis of gefitinib. An efficient and large scale convergent synthesis of
epidermal  geowth factor  receptor-tyrosine kinase inhibitors Gefitinib approved by U.S.
FDA for the treatment of non- cell lung cancer. The formation of 4-anilinoquinazolines
are  achieved  in  a  simple  one-  pot  reaction  of  suitable  formamide  intermediates  and
substituted anilines involving Dimroth rearrangement, thereby avoiding the need to make
quinazolin-4(3 H)- one intermediates which require a large experimental inputs. Using this
process we have produced drug candidates 1 with overall yield of 66% from 4-methoxy-5-
[3-(4-  morpholinyl)  propoxyl  ]-2-  nitrobenzonitrite  and  2  with  63%  from  4,5-bis(2-
methoxyethoxy)-2-nitrobenzonitrite on a multigram scale.
 Madireddy Venkataramana, et al.49, Degradation pathway for gefitinib is established as
per  ICH  recommendations  by  validated  and  stability  indicating  reverse  phase  liquid
chromatographic  method.  Gefitinib  is  subjected  to  stress  conditions  of  acid,  base,
oxidation, thermal and photolysis.  Significant  degradation is observed in acid and base
stress  conditions.  Two  impurities  are  studied  among  which  one  impurity  is  found
prominent degradant. The stress samples are assayed against a qualified reference standard
and the mass balance is found close to 99.5%. Efficient  chromatographic separation is
achieved on a Agilent  make XDB-C18, 50 × 4.6 mm with 1.8 µm particles stationary
phase  with  simple  mobile  phase  combination  delivered  in  gradient  mode  and
quantification is carried at 250 nm at a flow rate of 0.5 ml /·min. In the developed RPLC
method the resolution between gefitinib and the potential impurities is found to be greater
than 5.0. Regression analysis  shows an r value (correlation coefficient) of greater than
0.998 for gefitinib and the two potential impurities. This method is capable to detect the
impurities of gefitinib at a level of 0.01% with respect to test concentration of 0.5 mg /·ml
for a 4-µl injection volume. The developed RPLC method is validated with respect  to
specificity,  linearity  &  range,  accuracy,  precision  and  robustness  for  impurities
determination and assay determination.
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OBJECTIVES
The present study is to make an attempt to establish sensitive, economic and accurate methods for
the estimation of Gefitinib in pure and pharmaceutical dosage form. The proposed methods will
be validated as per ICH guidelines.
Literature survey reveals that only few analytical methods have been reported for the estimation
of Gefitinib in bulk drug and pharmaceutical formulations.
Hence  an attempt has  been made to  develop simple,  accurate,  sensitive,  rapid and  economic
method for the estimation of Gefitinib in pharmaceutical dosage forms using High Performance
Liquid Chromatography techniques.  These methods can also be applied for estimation of pure
drug.
.
 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
To develop and validate Reversed phase high performance liquid chromatography method for
estimation of Gefitinib in bulk drug and pharmaceutical dosage forms.
                   An attempt has been made to develop and validate the above mentioned methods to
ensure their accuracy, precision, robustness and other analytical method validation parameters as
mentioned in the ICH guidelines.
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PLAN OF WORK
Based  on the objective,  the plan of  the  work is  as  follows. Plan of  work was  designed  into
following ways  
1.  Selection of analytical techniques.
2.  Selection of analytical concentration ranges.
3.  Selection of analytical method.
4.  Selection of mobile phase.
5. Method development and optimized chromatographic condition.
 Selection of wavelength
 Choice of chromatographic method
6.  Validation of developed HPLC method as per ICH guidelines. 
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INSTRUMENT AND CHEMICAL REAGENTS :
CHEMICALS AND REAGENTS
S. NO. CHEMICALS/STANDARDS AND REAGENTS GRADE
1 Ortho-phosphoric acid AR
2                                 Triethylamine AR
3 Trifluoro aceticacid AR
4 Methanol HPLC
5  Water Milli Q
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INSTRUMENTS AND EQUIPMENTS:
S.NO.
INSTRUMENTS
AND EQUIPMENTS SOFTWARE MODEL COMPANY
1 HPLC EZ Chrome 1120 AGILENT
2 HPLC Clarity LC10ATvp SHIMADZU
3 Weighing Balance N/A AUX 220 SHIMADZU
4 Sonicator N/A N/A EQUITRON
5 pH Meter N/A LP139S POLMON
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GEFITINIB:
Structure:
Molecular Formula: C 22H 24 CIFN 4 O 3 
Molecular Weight: 446.902 g/mol
Chemical Name:   N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4yl) propoxy ] 
quinazolin-4-amine.
Description:  A white to yellow colour powder
Melting Point: 192-194 0C
Category: Antineoplastic Agents, Protein Kinase Inhibitors
Solubility: sparingly soluble in aqueous media but readily soluble in organic solvents
Dosage: 250mg per day with meal
Metabolism: Hepatic
Bioavailability: 59% (oral)
Toxicity:  The acute toxicity of gefitinib up to 500 mg in clinical studies has been low. In non-
clinical studies, a single dose of 12,000 mg/m2 (about 80 times the recommended clinical dose on
a mg/m2 basis) was lethal to rats. Half  this  dose caused no mortality in mice.  Symptoms of
overdose include diarrhea and skin rash.
Absorption: Absorbed slowly with oral administration.
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Mechanism of Action:
Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the
adenosine  triphosphate  (ATP)-binding  site  of  the  enzyme.  Thus  the  function  of  the  EGFR
tyrosine kinase in activating the R as signal transduction cascade is inhibited; and malignant cells
are inhibited. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also
referred to as Her1 or ErbB-1. EGFR is over expressed in the cells of certain types of human
carcinomas - for example in lung and breast  cancers.  Over expression leads to inappropriate
activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled
cell proliferation.
ANTICANCER
                          Cancer is a term used for diseases in which abnormal cells divide without
control and are able to invade other tissues. Cancer cells can spread to other parts of the body
through the blood and lymph systems. Anticancer drugs either kill the cancer cells or modify
their growth.  Validation of new analytical methods for estimation of anticancer drug is required.
In view of the need for a suitable method for routine analysis in combined formulations, attempts
are  made  to  develop  simple,  precise  and  accurate  analytical  methods  for  simultaneous
estimations  of  ingredients  and  extend  it  for  their  determination  in  formulation.  Analytical
validation is the corner stone of the process validation. Without a proven measurement system it
is impossible to confirm whether the manufacturing process has done what it supports to do.
Hence there is a need to validate the new methods developed. Various classes of drugs available
are
CLASSIFICATION:
1. Alkylating Agents
 Nitrogen mustards: Melphalan, Cyclophosphamide, Ifosfamide
 Nitrosoureas
 Alkylsulfonates
2. Antimetabolites
 Folate Antagonists: Methotrexate
 Purine antagonists:Fludarabine,mercaptopurine
 Pyrimidine antagonists: 5-Fluorouracil, Cytarabibe
3. Natural Products
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a. Plant Products
 Vinca Alkaloids: Vincristine, Vinblastine
 Taxanes: P
 aclitaxel
 Camptothecins: Irinotecan
b. Microorganism Products
 Antibiotics: Doxorubicin, Bleomycin
 Enzymes: L-Asparaginase
Miscellaneous
 Hydroxyurea
 Imatinib Mesylate
Hormones and Antagonists
 Corticosteroids: Prednisone, Dexamethasone
 Estrogens: Ethinyloestradiol
 Antiestrogens: Tamoxifen
 Progesteron derivative: Megestrol Acetate
Pharmacokinetics: 
Gefitinib  is  absorbed  slowly  after  oral  administration  with  mean  bioavailability  of  60%.
Elimination is by metabolism and excretion in feces. The elimination half life is about 48 hours.
Daily  oral  administered  of  gefitinib  to  cancer  patients  resulted  in  a  2-fold  accumulation
compared to single dose administered. Steady state plasma concentrations are achieved within 10
days.  
Absorption and Distribution: Gefitinib is slowly absorbed, with peak plasma levels occurring
3-7 hours after dosing and mean oral bioavailability of 60%. Bioavailability is not significantly
altered by food. Gefitinib is extensively distributed throughout the body with a mean steady state
volume  of  distribution  of  1400  L following  intravenous  administration.  In  vitro binding  of
gefitinib  to  human  plasma  proteins  (serum  albumin  α  l-acid  glycoprotein)  is  90%  and  is
independent of drug concentrations.
 Metabolism and Elimination: Gefitinib undergoes extensive hepatic metabolism in humans,
predominantly by CYP3A4. Three sites of biotransformation have been identified: metabolism of
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the N-propoxymorpholino-group, demethylation of the methoxy- substitution on the quinazoline,
and oxidative defluorination of the halogenated phenyl group.
Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half life
values of 595 ml/min and 48 hours, respectively, after intravenous administration. Excretion is
predominantly via feces (86%), with renal elimination of drug and metabolites accounting for
less than 4% of the administered dose.
Pharmacology
Adverse Effects: 
  As gefitinib is a selective chemotherapeutic agent, its tolerability profile is better than previous
cytotoxic agents. Adverse drug reactions (ADRs) are acceptable for a potentially fatal disease.
Acne is  reported very commonly.  Other  common adverse  effects  (≥1% of patients)  include:
diarrhoea,  nausea,  vomiting,  anorexia,  stomatitis,  dehydration,  skin  reactions,  paronychia,
asymptomatic elevations of liver enzymes, asthenia, conjunctivitis, blepharitis Infrequent adverse
effects (0.1–1% of patients) include: interstitial lung disease, corneal erosion, aberrant eyelash
and hair growth.
Pharmcodynamics: 
Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with
transmembrane  cell  surface  receptors,  including  the  tyrosine  kinases  associated  with  the
epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many
normal cells and cancer cells
Drug Interactions: 
In human liver microsome studies, gefitinib had no inhibitory effect on CYP1A2, CYP2C9, and
CYP3A4 activities at concentrations ranging from 2-5000 ng/ml. At the highest concentration
studied (5000 ng/ml), gefitinib inhibited CYP2C19 by 24% and CYP2D6 by 43%. Exposure to
metoprolol, a substrate of CYP2D6, was increased by 30% when it was given in combination
with gefitinib (500 mg daily for 28 days) in patients with solid tumors. 
                     Rifampicin, an inducer of CYP3A4, reduced mean AUC of gefitinib by 85% in
healthy male volunteers  Concomitant administration of itraconazole (200 mg QD for 12 days),
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an  inhibitor  of  CYP3A4,  with  gefitinib  (250  mg  single  dose)  to  healthy  male  volunteers,
increased mean gefitinib AUC by 88%. 
Co-administration of high doses of ranitidine with sodium bicarbonate (to maintain the gastric
pH above pH 5.0) reduced mean gefitinib AUC by 44 %.
                     International Normalized Ratio (INR) elevations and/or bleeding events have been
reported in some patients taking warfarin while on IRESSA therapy. Patients taking warfarin
should be monitored regularly for changes in prothrombin time or INR.
Therapeutic uses
 It is used in treating non-small cell lung cancer
 Effective in treating non cancer related TNF-α mediated inflammatory diseases including
autoimmune and non- autoimmune diseases.
 Used in the treatment of certain types of cancer.
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     Estimation of Gefitinib by RP-HPLC method.
Apparatus and software
The  Agilent  1120  Compact  LC  HPLC  system consisting  of  gradient  pump (4MPa  or
40barr), Rheodyne  injector, UV variable detector, Standard cell and Agilent syringe (50µl) and
also  HPLC  LC-10  ATvp  instrument  with  clarity  software  was  used.  The  separations  were
achieved on a Agilent column 5µm 4.6x250mm with UV detection at 246nm. Analytical weighing
balance (Shimadzu AUX 220) was used for weighing, sonicator (EQUITRON-230VAC, 50Hz)
vacuum pump (SUPER FIT 110336), Millipore filtration kit (TARSONS) with PALL membrane
for solvents and sample filtration were used throughout the experiment. The EZ Chrome Elite
software was used for acquisition, evaluation and storage of chromatographic data.
Reagents:
Analytically  pure  sample  of  Gefitinib  procured  as  gift  sample  by  celon  laboratories
(Hyderabad). The drug was used without further purification.  HPLC grade Methanol (Merck),
Pharmaceutical  formulation  gefitinib  (Iressa)  tablets  (label  claim  250mg)  Manufactured  by
Astrazeneca Pharmaceuticals Limited was used in the HPLC.  HPLC grade water obtained in-
house by  using  Direct-Q3  with  pump  (Elec.  Ratings:  100-230V  of  50-60Hz  100VA)  water
purification system (made in France) were used in HPLC study. 
Mobile phase:
A number of trials were made to find out the ideal solvent system (mobile phase) for
eluting the drug. The mobile phase containing Methanol: Water (60:40), Potassium  dihydrogen
phosphate buffer:  Methanol (50:50),  Methanol:  Glacial  acetic  acid buffer pH 3.0 (60:40) and
Methanol:  Di  sodium  hydrogen  phosphate (80:20) was tried. Better peak  and adequate
retention time were obtained with the ratio of 0.1% triflouroacetic acid of pH 3.0(adjusted with
Triethylamine): Methanol (HPLC grade) (35:65).
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Preparation of buffer Solution (0.1% Triflouro acetic acid):
1750µl of Ortho-phosphoric acid was diluted to 1000mL using water and pH was adjusted to 3.0
by using C6H15N (Triethylamine). This solution was  filtered through a 0.45µm nylon filter paper
(PALL) and degassed by ultrasonicator.
Preparation of Mobile Phase:
Transferred 1000 ml of  above solution and 1000 ml of methanol  to the mobile phase
bottles  separately.  HPLC  experiments  were  carried  out  using  binary  pump  A  containing
triflouroacetic acid(0.1%) and pump B containing Methanol in the ratio of 35:65.
Diluent preparation:
Mixture of   triflouroacetic acid   and Methanol was used as diluent. Transferred 35 ml of
triflouroacetic acid buffer to a 100 ml beaker and add 65 ml of Methanol.
 Preparation of Standard Stock Solution of  Gefitinib:
50 mg of gefitinib standard was accurately weighed and transferred to a 50ml volumetric
flask dissolved in 10 ml of methanol and sonicated for 10mins and made up with methanol to give
a solution containing 1000µg/ml. (stock solution ‘A’) From this stock solution, pipette out 5ml
placed in  to 50ml volumetric  flask and volume was made up to mark with diluent to give a
solution containing 100µg/ml (stock solution ‘B’).  From the above 0.5ml, 1ml, 1.5ml, 2ml, 2.5ml
and 3mL of  solutions  were pipetted out into two separate 10 mL volumetric flasks and volume
was made up to the mark with the diluent used. This gave the concentration of 5, 10, 15, 20, 25
and 30µg / ml. These six dilutions of Gefitinib were prepared and are estimated in HPLC.
     After several trials with different combination of solvents, 0.1% triflouro acetic acid:
methanol in the ratio 35:65 (v/v) by adjusting final pH 3.0 was selected because it gave a peak
with retention time (Rt) of Gefitinib (3.8mins). Wavelength was selected by scanning the standard
drug over a wide range of wavelength 200nm to 400 nm.
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 Table no: 1 Optimized Chromatographic conditions of Gefitinib
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S. No Parameters Gefitinib
1 Mobile phase optimized Triflouroaceticacid (0.1%)
: Methanol  (35:65)
2 Stationary phase C18 5µm  250  X  4.6  mm
(Agilent)
3 Flow rate (ml/min) 1
4 Run  time( min) 10
5 Column Temperature OC 25±1
6 Volume of Injection (µl) 20
7 Detection  Wavelength
(nm)
23232
246 nm
8 Retention time Rt 3.8min
VALIDATION
Table  no:2.  Characteristic  parameters  of  calibration  equation  for  the  proposed
HPLC method for Estimation of Gefitinib
Parameters Gefitinib
Acceptance
criteria
Calibration range (µg mL-1 ) 5-30 ----
Detection limit ( µg mL-1 ) 1.481 ----
Quantification limit (µg mL-1) 4.489 ----
Slope (m) 759565 -----
Intercept (c) 100006 ----
Correlation coefficient 0.998 NLT O.995
Theoretical plates 3799 NLT 2000
Tailing factor 1.20992 NMT 2
 Y = m x +c, where C is the concentration of compound in µg ml-1 and Y is the peak area.
Assay of Gefitinib in Tablets:
Twenty tablets were weighed and finely powdered. An accurately weighed quantity of the
powder equivalent to 100 mg of Gefitinib was transferred to 100 ml volumetric flask containing
40 ml of mobile phase and the contents of the flask were sonicated  for  15 min, to ensure the
complete solubility of the drug, then the mixture was made up to 100ml with mobile phase.
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The resulting solution was thoroughly mixed and filtered through a 0.45 µm membrane
filter. From this solution, required dilutions for HPLC method were prepared within the linearity
range using mobile phase as solvent.  
                   Fig. 1    STANDARD
                        Fig. 2   SAMPLE
Table no: 3  Calculation of Percentage Purity
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STANDARD AREA     20417132 ASSAY PERCENTAGE
SAMPLE AREA     20474693 100.28 % w/w
VALIDATION
Standard Area = 20417132
Sample Area = 20474693
Percentage Purity = Sample Area / Standard Area × 100
                                      =  20474693 / 20417132 × 100
                              = 100.28 % w/w
       
VALIDATION  OF  ANALYTICAL  METHOD:  Validation  of  an  analytical  method  is  the
process to establish by laboratory studies that the performance characteristic of the method meets
the requirements for the intended analytical application. 
1.  SPECIFICITY:
The specificity of the method was evaluated with regard to interference due to presence of
any other excipients. The figure no: 3 shows that drug was clearly separated from its excipients.
Thus, the HPLC method presented in this study is selective.
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Fig. 3 Chromatogram of blank
Blank interference: 
              A study to establish the interference of blank was conducted. Mobile phase was injected
as per the test method. 
Chromatogram of blank not showed any peak at the retention time of   analyte   peak.
Fig. 4  Chromatogram of Gefitinib showing retention time (Rt) 
2.  ACCURACY
Accuracy of an analytical method is the closeness of test results obtained by that method to the
true value. The accuracy of an analytical method should be established across its range. Accuracy
is performed in three different levels, each level in triplicate for Gefitinib using standards at 50%,
100% and 150% are shown in Fig. 5 ,6 ,7 . Each sample is analyzed in triplicate for each level.
From the results, % recovery is calculated are shown in Table no: 4 and 5.   
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Fig. 5  Chromatogram of Gefitinib showing 50% accuracy
Fig. 6  Chromatogram of Gefitinib showing 100% accuracy
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Fig. 7  Chromatogram of Gefitinib showing 150% accuracy.
                                          
                                         Table no: 4. Accuracy of Gefitinib
S.NO Recovery Level (%)
RP-HPLC
Standard
Area
Area of
Gefitinib
% Recovery
1 50 8231162 8214874 99.8
2 100 8231162 8291399 100.7
3 150 8231162 8240493 100.1
             Mean of three determinations
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Table no: 5.  Results of recovery of Gefitinib
S.NO Recovery Level in% Area Mean % Recovery ±RSD
1 50 8242161
8214874±0.292 50 8198334
3 50 8204121
4 100 8236132
8291399±0.635 100 8189411
6 100 8293009
7 150 8213212
8240493±0.278 150 8198428
9 150 8242523
3.  LINEARITY
Linearity of the proposed HPLC method for determination of Geftinib was evaluated by
analyzing a series of different concentrations of standard drug. In this study five concentrations
were chosen ranging between 5-30µg/ml. By using the stock solution ‘B’, aliquots of 5, 10, 15,
20, 25 and 30µg/ml were prepared with diluent  six dilutions of each of the above mentioned
concentrations were prepared separately and from these six dilutions, 20 µl  each concentration
was injected three times and obtained information on variation in the peak area response of pure
analytes was plotted against corresponding concentrations and result was shown in Table no: 6.  
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                                     Fig. 8  Linearity curve of Gefitinib
Fig. 9  Chromatogram of Gefitinib showing a concentration of 5µg/ml
Fig. 10  Chromatogram of Gefitinib showing a concentration of 10µg/ml
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Fig. 11  Chromatogram of Gefitinib showing a concentration of 15µg/ml
Fig. 12  Chromatogram of Gefitinib showing a concentration of 20µg/ml
Fig. 13  Chromatogram of Gefitinib showing a concentration of 25µg/ml
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Fig.  14  Chromatogram of Gefitinib showing a concentration of 30µg/ml
                            Table no: 6.  Linearity data for Gefitinib
S.No Gefitinib
Concentration in µg/ml Peak area
1 5 5203009
2 10 8231162
3 15 12515723
4 20 16107083
5 25 20417132
6 30 23757913
avg of 6 determinations
4.  PRECISION
Precision of  the  analytical  method  was  studied  by  analysis  of  multiple  sampling  of
homogeneous sample. The precision expressed as % RSD were given in Table no. 7.
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Method  reproducibility was  demonstrated  by  repeatability  and  intermediate  precision
measurements of peak area, retention time and peak symmetry parameters of HPLC method for
each title ingredients. 
Repeatability (of results of measurements) - the closeness of the agreement between the results of
successive  measurements  of the same substance  carried out  under  the same conditions  (same
measurement procedure, the same observer, the same measuring instrument, used under the same
conditions, the same location, and repetition over a short period of time) of measurement.
The  repeatability and intermediate precision were carried out at 100% concentration for
Gefitinib. The obtained results within and between the days of trials were in acceptable range
indicating good precision of the proposed methods were given in Table no 7 and 8
    Fig. 15  Chromatogram of Gefitinib showing intraday (Forenoon) precision
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Fig. 16  Chromatogram of Gefitinib showing intraday (Afternoon) precision
             Table no: 7.  Intraday (Repeatability) study results by HPLC
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S.NO FORENOON AFTERNOON
INJECTION AREA INJECTION AREA
1 Injection 1 19761211 Injection 1 20685542
2 Injection 2 20390438 Injection 2 20664991
3 Injection 3 20332497 Injection 3 20716784
4 Injection 4 20547346 Injection 4 20397066
5 Injection 5 20474693 Injection 5 20412069
6 Injection 6 20444825 Injection 6 20210929
Average 20325168 Average 20719141
SD 282797.1 SD 204577.6
%RSD 1.406 %RSD 0.987
VALIDATION
Fig. 17  Chromatogram of Gefitinib showing interday (day1) precision
    
Fig. 18  Chromatogram of Gefitinib showing interday (day2) precision
    
Department of Pharmaceutical Analysis Page 64
VALIDATION
     Table no: 8. Inter day (intermediate precision) study results by HPLC
5.  LIMIT OF DETECTION(LOD) AND LIMIT OF QUANTITATION(LOQ)
Table no: 9. LOD & LOQ of  Gefitinib
PARAMETERS µg/ml
LOD 1.481
LOQ 4.489
.
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S.NO DAY 1 DAY 2
INJECTION AREA INJECTION AREA
1 Injection 1 19761211 Injection 1 20456575
2 Injection 2 20390438 Injection 2 20934578
3 Injection 3 20332497 Injection 3 20582365
4 Injection 4 20547346 Injection 4 20222589
5 Injection 5 2474693 Injection 5 20456238
6 Injection 6 20444825 Injection 6 20589632
Average 20325168 Average 20540329
SD 285797.1 SD 234382
%RSD 1.407 %RSD 1.141
VALIDATION
LOD and LOQ were calculated according to ICH recommendations where the approach is based
on the signal-to-noise ratio. Chromatogram signals obtained with known low concentrations of
analyte was compared with the signals of blank samples. A signal-to-noise ratio 3:1 and 10:1 was
considered for calculating LOD and LOQ respectively. The values of LOD and LOQ were given
in Table no. 9
6.  SYSTEM SUITABILITY:
                        Table no. 10. Results of system suitability parameters
Parameters Data obtained for Gefitinib
Theoretical plates per meter 15196
Theoretical plates per column 3799
Symmetry factor/Tailing factor 1.2099
Theoretical  plates per meter were calculated from the data obtained from the peak using the
following expression
                                n = (5.54Vr2)/LWh2
Theoretical plates per column were calculated from the data obtained from the peak.
                                  n = (5.54Vr2)/Wh2
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Where, “n” is the number of theoretical plates per meter. “Vr” is the distance along the base line
between  the  point  of  injection and perpendicular  dropped from the maximum of the peak of
interest and “Wh” is the width of the peak of interest at half peak height Table No.10
   
Tailing factor is also known as symmetry factor of peak and it was calculated from the following
expression
                                      Symmetry factor = a/b
Where, a = ½ width of the peak at one twentieth of the peak height
          b= ½ width of the peak at one twentieth of the peak height
7.  RUGGEDNESS OF TEST METHOD: 
System to system/ Analyst to Analyst/column to Column variability:
System to  system/  Analyst  to  Analyst/column  to  column variability  study was  conducted  on
different  HPLC systems,  different  columns and  different  analysts  under  similar  conditions  at
different times. Six samples were prepared and each was analyzed as per test method. The relative
standard  deviation  for  Gefitinib  were  found  to  be  below  2  % on  the  columns,  systems  and
analysts.  Comparison of both the results  obtained  on two different  HPLC systems/Analyst  to
Analyst/ column to column variability. 
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i)  Shimadzu system:
                                                       Table No:11
    Tablet ID    % Assay of
     Gefitinib
         Mean            SD         %RSD
           1        99.24
    98.59 0.56           0.56           2        98.19
           3        98.34
ii) Agilent System:
                                                       Table No:12
     Tablet ID    % Assay of
     Gefitinib
         Mean            SD         %RSD
           1         99.32
         98.94        0.806    0.81           2         98.02
           3         99.5
ACCEPTANCE CRITERIA: 
The % RSD of Gefitinib from the six sample preparations should be not more than 2.0 %. 
The percentage recovery of Gefitinib should be between  95.0 % to 105 %. 
OBSERVATION:
The %RSD was found within the limits
INTERMEDIATE PRECISION:
                                                                Day 1:
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                                                       Table No:13
     Tablet ID    % Assay of
     Gefitinib
         Mean            SD         %RSD
           1         99.87
         99.26        0.69    0.69           2         99.43
           3         98.5
                                                                  Day-2
                                                             Table No:14
     Tablet ID    % Assay of
     Gefitinib
         Mean            SD         %RSD
           1         99.14
         98.71        1.41    1.42           2         98.24
           3         98.77
8.  ROBUSTNESS:
i) Effect of variation of flow rate; 
A  study  was  conducted  to  determine  the  effect  of  variation  in  flow  rate.  Standard  solution
prepared as per the test method was injected into the HPLC system using rates 0.8 ml/min and 1.2
ml/min flow. 
Gefitinib were resolved from all other peaks and the retention times were comparable with those
obtained for mobile phase having flow rates 1.0 ml/min.
ACCEPTANCE CRITERIA: 
The Tailing Factor of Gefitinib standards should be NMT 2.0 for variation in flow. 
OBSERVATION: 
The Tailing Factor for Gefitinib are found to be within the limits. 
ii) Effect of Variation of temperature: 
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A study was conducted to determine the effect  of variation in temperature.  Standard solution
prepared as per the test method was injected into the HPLC system at 25 0C temperature.   
The  system  suitability  parameters  were  evaluated  and  found  to  be  within  the  limits  for
temperature change of 25 0C. 
 Gefitinib were resolved from all other peaks and the retention times were comparable with those
obtained for mobile phase having ambient temperature. 
ACCEPTANCE CRITERIA: 
The Tailing Factor of Gefitinib standard and sample solutions should be NMT 2.0 for Variation in
temperature. 
iii) Effect of variation in pH
Gefitinib standard should be NMT 2.0 for Variation in pH. A study was conducted to
determine the effect of variation in pH. Standard and sample solutions were prepared as per the
test method and injected into the HPLC system using pH 2.7 and 3.5. The system suitability
parameters were evaluated and found to be within the limits for pH 2.7 and 3.5. 
Gefitinib were solved from all other peaks and the retention times were comparable with those
obtained for mobile phase having pH 3.0 . 
Form the above study it was established that the allowable variation in pH 2.7 and 3.5. 
ACCEPTANCE CRITERIA: 
The %RSD Factor Gefitinib were found to be within the limits.
                     Table No:15
Parameters Optimum
range
Conditions in
procedure
Remarks
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Flow rate
ml/min 0.8-1.2
1.0
Increase  in  flow  rate  resulted  in  early
elution  of  all  two  active  ingredients.
Decrease  in flow rate in late elution of
all  two  actives  but  still  within  the
proposed run time. 
Temperature
20-35 0C 25 0C
Increase in temperature resulted in early
elution  of  all  two  active  ingredients.
Decrease in temperature resulted in late
elution of all two actives but still within
the proposed run time 
pH
2.7 -3.5 3.0
Gefitinib  were  solved  from  all  other
peaks  and  the  retention  times  were
comparable  with  those  obtained  for
mobile phase having pH 3.0 .
CONCLUSION: From the above results it is concluded that the method was robust. 
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RESULTS AND DISCUSSION
SYSTEM SUITABILITY:             
 The system suitability parameters  were evaluated.  The %RSD for six replicate
injections of Gefitinib is with in the limits. The tailing factors for Gefitinib peaks
were 1.20. The theoretical plates for Gefitinib are 3799 were found to be with in the
limits. The system suitability parameters were evaluated and found to be within the
limits. 
PRECISION:
The percentage assay of six replicate injections of the drugs were performed and the
percentage RSD of individual drugs were calculated and found to be  which are
found to be with in the limits the %RSD is less than 2.   
ACCURACY:
Accuracy of the method was performed with concentration level of 50%, 100% and
150% and the percentage recovery was calculated and found to be with in the limits
of 95% to 105% and the %RSD is also less than 2.
LINEARITY:
The linearity of the method was tested for Gefitinib at 6 concentration levels and
the correlation coefficient was calculated for the drugs and found to be with in
limits (not less than 0.995).  
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SPECIFICITY:
There was no absolute interference from placebo preparations at retention time of
Gefitinib.    This shows that the method is specific.
Placebo interference:
It  was  concluded  that  there  is  no  interference  with  placebo  as  no  peaks  were
observed at the retention time of Gefitinib peaks. 
Interference from the degradation products:
Purity angle was found to be less than threshold angle in all forced degradation
studies without  having signs of purity flags.  All  degradant  peaks were resolved
from Gefitinib peaks in the chromatograms of all samples and found that there was
no interference with the main drug peaks.
RUGGEDNESS:
System  to  system/  Analyst  to  Analyst/column  to  column  variability  study  was
conducted on different HPLC systems. Six samples were prepared and each was
analyzed as  per  test  method.  The relative  standard deviation for  Gefitinib were
found to be below 2% on the columns, systems and analysts. 
ROBUSTNESS:
The  robustness  of  the  method  was  tested  with  the  variation  in  Flow  rates,
Temperature and Buffer pH. The %RSD of the varied parameters is calculated for
both the drugs which are found to be with in the limits. The method was found to be
robust.
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                                         CONCLUSION
                  In the present investigation we have validated a simple, sensitive, precise and accurate
RP-HPLC method for  the quantitative estimation of Gefitinib in pharmaceutical  formulations.
The results expressed in Tables for RP- HPLC method are promising. The RP- HPLC method is
more sensitive, precise and accurate compared to the spectrophotometric methods. This method
can  be  used  for  the  routine  determination  of  Gefitinib  in  bulk  drug  and  in  pharmaceutical
formulations as per ICH guidelines.
Chromatographic conditions :
Mobile phase                                   : Triflouroaceticacid (0.1%) : Methanol (35:65)
Column                                           : C18 5µm 250 × 4.6 mm ( Agilent)
Flow rate                                         : 1ml / min
Detector wavelength                      : 246 nm
Injection volume                            : 20µl
Column oven temperature              : 25±1°c
Runtime                                          : 10 minutes
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